Bolstered by promising PhIIb snapshot, uniQure plays catch-up with Spark in the race to a hemophilia B gene therapy
The pivotal lead switch that uniQure executed late last year appears to have paid off, as the gene therapy pioneer offers some positive, if early …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
